EIC Accelerator

Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.

Noah Labs develops innovative technology aimed at the early detection of cardiovascular diseases through voice analysis. Utilizing advanced machine learning software, the company has created a digital health platform that allows patients to record their voices using a smartphone. This platform incorporates patient monitoring and digital biomarkers, providing personalized and predictive virtual care in the comfort of their homes. By focusing on voice-based diagnostics, Noah Labs seeks to empower individuals with cardiovascular conditions to lead healthier and longer lives.

Premium Fertility develops an assisted reproductive technology for embryo transfer, featuring a direct embryo transfer system that integrates optical, microfluidic, and automated components to enable clinicians to place embryos with greater precision and consistency while addressing uncertainties in attachment.

Premium Fertility develops an assisted reproductive technology for embryo transfer, featuring a direct embryo transfer system that integrates optical, microfluidic, and automated components to enable clinicians to place embryos with greater precision and consistency while addressing uncertainties in attachment.

Noah Labs develops innovative technology aimed at the early detection of cardiovascular diseases through voice analysis. Utilizing advanced machine learning software, the company has created a digital health platform that allows patients to record their voices using a smartphone. This platform incorporates patient monitoring and digital biomarkers, providing personalized and predictive virtual care in the comfort of their homes. By focusing on voice-based diagnostics, Noah Labs seeks to empower individuals with cardiovascular conditions to lead healthier and longer lives.

TetraKit Technologies is a Copenhagen-based company founded in 2021 that specializes in a click chemistry-based radiochemical platform aimed at developing therapeutics for metastatic cancer. The company offers a targeted radionuclide therapy and nuclear imaging platform for cancer diagnosis, utilizing radiopharmaceuticals such as fluorine-18 and astatine-211 for positron emission tomography (PET) imaging and targeted alpha-radionuclide therapy. TetraKit's innovative approach incorporates proprietary click chemistry and a modular design, which allows for rapid and mild labeling conditions across a variety of molecules. This platform enhances the efficiency of production processes in the field of radiopharmaceuticals, enabling medical professionals to leverage advanced technologies in cancer treatment and imaging.

TetraKit Technologies is a Copenhagen-based company founded in 2021 that specializes in a click chemistry-based radiochemical platform aimed at developing therapeutics for metastatic cancer. The company offers a targeted radionuclide therapy and nuclear imaging platform for cancer diagnosis, utilizing radiopharmaceuticals such as fluorine-18 and astatine-211 for positron emission tomography (PET) imaging and targeted alpha-radionuclide therapy. TetraKit's innovative approach incorporates proprietary click chemistry and a modular design, which allows for rapid and mild labeling conditions across a variety of molecules. This platform enhances the efficiency of production processes in the field of radiopharmaceuticals, enabling medical professionals to leverage advanced technologies in cancer treatment and imaging.

Neurescue ApS, headquartered in Copenhagen, Denmark, specializes in developing innovative medical devices aimed at addressing cardiac arrest and hemorrhage. Established in 2014, the company has introduced its flagship product, the safeREBOA device, which is recognized as the first computer-aided aortic occlusion catheter designed to enhance the care of emergency patients. Neurescue's commitment lies in improving resuscitation rates and extending critical treatment time through advanced cardiovascular solutions. The organization is focused on advancing the clinical utility of its devices to ultimately save lives in emergency situations.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

MindPeak GmbH is a technology company based in Hamburg, Germany, founded in 2018. It specializes in developing artificial intelligence software tools aimed at enhancing the accuracy and efficiency of cancer diagnostics. The company's flagship product, BreastAI, is designed for the quantification of breast cancer immunohistochemistry (IHC) and can be integrated into third-party software systems. MindPeak's solutions automate tissue diagnostics, enabling pathologists to identify and quantify tumorous regions and detect breast cancer cells more effectively. By streamlining tasks such as cell and biomarker quantification, MindPeak's tools allow cancer specialists to focus on critical decision-making in clinical environments, ultimately improving patient care while making diagnostic processes more accessible and cost-effective.

JaxBio develops AI-driven diagnostic technology for cancer, using AI-based chips for genetic and epigenetic profiling and array-based cancer tests to enable a simple, sensitive blood test for cancer detection and monitoring. Its technology identifies biomarker sets that distinguish cancer types and subtypes across stages, supporting early detection, disease monitoring, and prediction of treatment response.

Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Diamante is a company based in Verona, Italy, that specializes in the development and manufacturing of diagnostic devices for autoimmune diseases, utilizing innovative nanomaterials. Founded in 2016, the company leverages plants as bioreactors to produce nanoparticles derived from modified plant viruses. This approach allows Diamante to create advanced tools for diagnosing and potentially treating autoimmune conditions, focusing on sustainable and efficient production methods. Through its research and development efforts, Diamante aims to contribute significantly to the field of autoimmune disease therapy.

Implicity is a developer of a remote monitoring platform that focuses on patients with connected cardiac implants, such as pacemakers and defibrillators. The company's software-as-a-service (SaaS) platform utilizes artificial intelligence to sort and summarize patient data, assessing the criticality of alerts based on the medical context of each individual. This technology allows cardiologists and healthcare professionals to automate the monitoring process, facilitating efficient oversight of patient health and enhancing the quality of care. By consolidating patient information and alerts on a single platform, Implicity aims to improve the management of cardiac conditions and support hospital teams in delivering optimal patient outcomes.

Omini is a biotechnology company based in Saint Mandé, France, founded in 2019. It specializes in the development of portable and multipurpose bio-sensing devices designed for immediate blood testing. Omini's biosensor platform enables the simultaneous detection of multiple biomarkers, providing personalized blood biomarker data that can be utilized to customize therapies and prevent acute crises in patients with chronic conditions. By leveraging multiplex electrochemical biosensor technology, the company offers affordable and accurate monitoring solutions that facilitate decentralized testing and at-home monitoring, ultimately helping to alleviate the burden on healthcare systems. Omini primarily serves general practitioners, aiming to enhance patient care through innovative diagnostic tools.

Implicity is a developer of a remote monitoring platform that focuses on patients with connected cardiac implants, such as pacemakers and defibrillators. The company's software-as-a-service (SaaS) platform utilizes artificial intelligence to sort and summarize patient data, assessing the criticality of alerts based on the medical context of each individual. This technology allows cardiologists and healthcare professionals to automate the monitoring process, facilitating efficient oversight of patient health and enhancing the quality of care. By consolidating patient information and alerts on a single platform, Implicity aims to improve the management of cardiac conditions and support hospital teams in delivering optimal patient outcomes.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Diamante is a company based in Verona, Italy, that specializes in the development and manufacturing of diagnostic devices for autoimmune diseases, utilizing innovative nanomaterials. Founded in 2016, the company leverages plants as bioreactors to produce nanoparticles derived from modified plant viruses. This approach allows Diamante to create advanced tools for diagnosing and potentially treating autoimmune conditions, focusing on sustainable and efficient production methods. Through its research and development efforts, Diamante aims to contribute significantly to the field of autoimmune disease therapy.

Omini is a biotechnology company based in Saint Mandé, France, founded in 2019. It specializes in the development of portable and multipurpose bio-sensing devices designed for immediate blood testing. Omini's biosensor platform enables the simultaneous detection of multiple biomarkers, providing personalized blood biomarker data that can be utilized to customize therapies and prevent acute crises in patients with chronic conditions. By leveraging multiplex electrochemical biosensor technology, the company offers affordable and accurate monitoring solutions that facilitate decentralized testing and at-home monitoring, ultimately helping to alleviate the burden on healthcare systems. Omini primarily serves general practitioners, aiming to enhance patient care through innovative diagnostic tools.

Scope Biosciences develops molecular diagnostics leveraging CRISPR-Cas technology. It originated as a spin-off from Wageningen University & Research. The company aims to provide actionable nucleic acid detection in healthcare and agriculture with high specificity for single-nucleotide differences and sensitivity to trace genetic material, packaged in a format that can be used outside traditional laboratory settings to support on-site decision making by clinicians and agricultural professionals.

Hawk Biosystems is a developer of a companion diagnostics platform that focuses on enhancing cancer diagnostics and precision medicine. The company's technology is designed to measure drug target function and disclose post-translational modifications and protein-protein interactions in pathology samples. By quantifying these interactions in single-cell and fixed tissue samples, Hawk Biosystems preserves the morphological integrity and cellular heterogeneity of the tissue. This capability allows medical practitioners and pharmaceutical companies to make informed treatment decisions for cancer, inflammation, and immune disorders. The platform aims to improve patient outcomes by ensuring that therapies are accurately targeted to those most likely to benefit, ultimately enhancing the quality of life for patients while also reducing overall drug costs.

O11 Biomedical GmbH is a spin-off from RWTH Aachen University's Institute for Applied Medical Engineering, specifically the Department of Biohybrids & Medical Textiles. The company specializes in liquid breathing technology aimed at treating hypercapnia, a condition characterized by elevated carbon dioxide levels in the blood. O11 Biomedical's innovative technology effectively binds carbon dioxide from intestinal fluid, facilitating its excretion through natural processes. By doing so, the company seeks to enhance both the survival and quality of life for patients afflicted with this respiratory condition.

Thirona is a software company that develops AI-powered medical imaging analysis tools and provides image analysis services for the healthcare industry. Its automated tools support the analysis of thoracic CT scans, chest X-rays, and retinal images, delivering accurate and repeatable measurements to help hospitals detect and mitigate diseases. The company offers software solutions and certified image analysis services that streamline imaging workflows and improve diagnostic precision.

Picterus is developing an app to diagnose jaundice in newborns, aiming to reduce the global infant mortality associated with this condition. The platform uses a patented color calibration card and smartphone camera for accurate image capture, providing healthcare professionals and caregivers with a reliable tool for early detection and timely intervention.

BioSimulytics is a company that specializes in creating AI-powered software tailored for drug researchers in the pharmaceutical industry. Its innovative platform integrates molecular chemistry, quantum physics, and advanced artificial intelligence to enhance the drug development process. By focusing on crystal-structure prediction, BioSimulytics enables researchers to accurately predict stable polymorphs, which significantly improves the speed, certainty, and quality of product data. This technology aims to streamline the development of pharmaceuticals, ultimately supporting researchers in their quest to bring new drugs to market more efficiently.

Molecular Attraction is a research and development firm focused on creating innovative solutions for vector-borne disease control and eradication. The company specializes in identifying biological compounds that can influence the behavior of various vector organisms, including mosquitoes, ticks, flies, and rodents. By utilizing sustainable technology and chemical blends, Molecular Attraction aims to provide effective, long-lasting, and low-maintenance pest control solutions. Their approach is designed to enhance the efficacy of vector-borne disease management while prioritizing environmental sustainability and cost-effectiveness within the pest control industry.

Strolll is a digital health company focused on improving mobility for people with neurological disorders. It develops a B2B digital therapeutics platform that delivers clinically validated rehabilitation software on off-the-shelf augmented reality glasses. The platform supports both in-clinic (synchronous) and at-home (asynchronous) therapy, enabling rehabilitation clinics to scale services, improve access, and reduce the cost of neurorehabilitation. By personalizing therapy, the solution aims to increase patient adherence and outcomes while streamlining administrative processes and delivering meaningful data to clinics.

Nimble Diagnostics is a company that offers a range of DNA testing services, including paternity testing, prenatal gender testing, family relationship testing, ancestry DNA testing, and DNA art. In addition to these services, the company provides cancer nutraceuticals, aiming to support patients' health and well-being. Nimble Diagnostics leverages the internet to deliver its offerings globally at affordable prices, maintaining a commitment to accessible molecular diagnostics. The company also focuses on developing medical monitoring devices that enhance patient care, particularly for individuals with medical implants. These devices enable continuous, non-invasive monitoring, allowing healthcare providers to transition from reactive to proactive care, thereby reducing clinical complications associated with implanted stents.